{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:25:43Z","timestamp":1773325543639,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1136\/ard.2006.064279","type":"journal-article","created":{"date-parts":[[2006,11,24]],"date-time":"2006-11-24T01:25:30Z","timestamp":1164331530000},"page":"565-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Adalimumab: a new modality for Beh\u00e7et's disease?"],"prefix":"10.1016","volume":"66","author":[{"given":"J A M","family":"van Laar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Missotten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P L A","family":"van Daele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Jamnitski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G S","family":"Baarsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P M","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2006.064279_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0165-5728(02)00208-4","article-title":"Vgamma9Vdelta2 T cells recovered from eyes of patients with Behcet\u2019s disease recognize non-peptide prenyl pyrophosphate antigens","volume":"130","author":"Verjans","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1136\/ard.2006.064279_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of behcet disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1136\/ard.2006.064279_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2004.08.004","article-title":"Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review","volume":"4","author":"Atzeni","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard.2006.064279_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Behcet\u2019s disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2006.064279_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/sarh.2003.50022","article-title":"Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis","volume":"33","author":"Stokes","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2006.064279_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.2006.064279_bib7","first-page":"98","article-title":"Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.064279_bib8","unstructured":"Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Beh\u00e7et\u2019s disease. Ey. Published Online First: 7 April 2006, doi: 10. 1038\/sj. eye. 6702352."},{"key":"10.1136\/ard.2006.064279_bib9","first-page":"705","article-title":"Beh\u00e7et\u2019s disease and the possibilities of modern tumour necrosis factor inhibiting medication","volume":"150","author":"Van Laar","year":"2006","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1136\/ard.2006.064279_bib10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2004.11.006","article-title":"The benefit\/risk profile of TNF-blocking agents: findings of a consensus panel","volume":"34","author":"Hochberg","year":"2005","journal-title":"Semin Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724193454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724193454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2006.064279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T14:03:47Z","timestamp":1736085827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724193454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0003496724193454"],"URL":"https:\/\/doi.org\/10.1136\/ard.2006.064279","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab: a new modality for Beh\u00e7et's disease?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2006.064279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Copyright 2007 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}